JAK

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

JAK

Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway.Members of the type I and type II cytokine receptor families depend on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways because they lack catalytic kinase activity. The receptors have two intracellular signal-transducing domains because they are paired polypeptides. Each intracellular domain contains a proline-rich region called a box1/box2 region that is close to the cell membrane and where JAKs bind. The two JAKs are brought close enough to phosphorylate one another after the receptor undergoes a conformational change following association with the corresponding cytokine or ligand. By further phosphorylating and activating STAT transcription factors, JAK autophosphorylation causes a conformational change within itself, enabling it to transduce the intracellular signal. When STATs are activated, they separate from their receptor and coalesce into dimers before moving into the cell nucleus, where they control the transcription of particular genes.

JAK related products

Cat No.	Product Name	CAS No.	Product Description
V4262	AT-9283 L-lactate	896466-76-5	AT-9283 L-lactate is a novel, potent multikinase inhibitor with potential antineoplastic activity and has the potential for the treatment of multiple myeloma.
V77246	APTSTAT3-9R		APTSTAT3-9R is a specific STAT3-binding peptide that can inhibit STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation.
V4261	AT-9283 HCl	896466-61-8	AT9283 is a novel, potent multikinase inhibitor with potential antineoplastic activity and has the potential for the treatment of multiple myeloma.
V78833	CMD178		CMD178 is a leading peptide that can continuously reduce the expression of Foxp3 and STAT5 by inhibiting the IL-2/s IL-2Rα signaling pathway and inhibit the development of Treg cells.
V77144	CMD178 TFA		CMD178 TFA is a leading peptide that can continuously reduce the expression of Foxp3 and STAT5 by inhibiting the IL-2/s IL-2Rα signaling pathway and inhibit the development of Treg cells.
V3114	FM-381	2226521-65-7	FM-381 (FM381) is a potent, specific, covalent reversible inhibitor ofJAK3 with anti-inflammatory activity.
V2144	FM-381 HCl	2226521-65-7	FM-381 HCl is a Chemical Probe For JAK3 and JAK3 specific reversible covalent inhibitor.
V80085	JAK-IN-29		JAK-IN-29 (compound 3) is a potent JAK inhibitor.
V79111	JAK-IN-33	3032404-49-9	JAK-IN-33 (compound 3 (R)) is a JAK inhibitor.
V3971	JANEX-1	202475-60-3	JANEX-1 (aslo known as WHI-P131) is a novel, potent and selective inhibitor of the Janus kinase 3 (JAK3) that selectively inhibits JAK3 with an IC50 of 78 µM and does not inhibit JAK1 and JAK2.
V80712	MC0704	3034176-57-0	MC0704 is a STAT3 inhibitor (antagonist) with IC50 of 2.13 μM.
V4974	NSC-42834	195371-52-9	NSC 42834 (also known as JAK2 Inhibitor V) is a novel, potent and specific inhibitor of JAK2 which inhibits JAK2-V617F and JAK2-WT autophosphorylation in a dose-dependent manner with IC50 values between 10 and 30 µM.
V81001	OK2		OK2 is a specific inhibitor of CCN2/EGFR interaction and effectively blocks CCN2/EGFR interaction via binding to the CT domain of CCN2.
V76674	OSM-SMI-10B		OSM-SMI-10B is an analogue of OSM-SMI-10.
V3111	Ritlecitinib (PF-06651600)	1792180-81-4	Ritlecitinib (PF-06651600) is a novel, potent, selective and irreversible/covalent JAK3inhibitor with the potential to treat autoimmune diseases such asarthritis and Alopecia areata.
V76478	STAT3-IN-15		STAT3-IN-15 is a potent, orally bioactive STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF).
V80001	Ten01		Ten01 has 5.0 nM inhibitory activity against JAK1 kinase.
V80248	Tofacitinib-13C3 (Tasocitinib-13C3; CP-690550-13C3)		Tofacitinib-13C3 is a 13C (carbon 13)-labeled tofacitinib.
V69739	Tubulin/JAK2-IN-1	2933938-46-4	Tubulin/JAK2-IN-1 is a dual (bifunctional) inhibitor of Janus kinase 2 (JAK2) and microtubules.
V0339	WP1066	857064-38-1	WP1066,an AG49 derivative, is a novel and potent inhibitor of Janus kinases-JAK2 and STAT3 with potential antitumor activity.